CRESY News Alert Cresud S.A.C.I.F. Y A. (CRESY) 10.52 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cresud S.A.C.I.F. Y A. (CRESY) 10.52 $CRESY

Cresud's (CRESY) CEO Alejandro Elsztain on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 5:12PM CST

CRESY: 10.52 (-0.11)

Cresud S.A.C.I.F. y A. net income of -ARS163.6M
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 5:28AM CST

CRESY: 10.52 (-0.11)

Cresud S.A.C.I.F. y A. Announces Results for the First Half 2015 ended December 31, 2014
PR Newswire - Mon Feb 09, 11:05PM CST
Cresud S.A.C.I.F. y A. (NASDAQ: CRESY, BASE: CRES), today announces results for the First Half 2015 ended December 31, 2014.
CRESY: 10.52 (-0.11)

Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Tue Nov 18, 4:40AM CST

MBI: 8.72 (+0.17), GD: 137.61 (-0.54), UPL: 15.67 (+0.84), BBRY: 10.09 (+0.23), RYAM: 17.58 (+0.36), OSTK: 22.45 (-0.13), INTC: 34.36 (+0.23), PTEN: 18.14 (+1.13), PCP: 205.54 (+1.37), JNJ: 99.62 (+1.18), SLM: 9.26 (-0.01), PWE: 2.45 (+0.02), TRQ: 3.06 (unch), IBM: 160.40 (+1.88), XCO: 2.52 (+0.20), BP: 41.93 (+0.59), NYT: 14.45 (+0.28), ORI: 14.95 (unch), NAVI: 22.37 (+0.16), DXM: 7.08 (-0.03), SD: 2.09 (+0.14), NEU: 469.55 (+0.43), NYCB: 16.37 (+0.07), PFE: 34.64 (-0.23), KW: 27.50 (+0.25), EDU: 18.79 (+0.01), WFC: 55.33 (+0.47), BYI: 83.27 (unch), CSX: 36.08 (-0.49), LRN: 16.56 (-0.06), NTP: 4.88 (-0.15), USB: 45.07 (-0.05), CRESY: 10.52 (-0.11), BWINB: 23.41 (+0.01), BCE: 44.74 (+0.14), USG: 29.53 (+0.90), STL: 13.87 (-0.16), BRK.B: 148.34 (-1.45), BRK.A: 222,555.00 (-1,905.00), RFP: 19.03 (+0.40), HOLX: 30.46 (+0.21)

Cresud Sacifya (CRESY) Downgraded From Hold to Sell
at The Street - Fri Nov 14, 8:30AM CST
Cresud Sacifya (CRESY) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D+.
CRESY: 10.52 (-0.11)

Cresud SACIF Has Returned 15.2% Since SmarTrend Recommendation (CRESY)
Comtex SmarTrend(R) - Wed Nov 12, 5:04PM CST
SmarTrend identified a Downtrend for Cresud SACIF (NASDAQ:CRESY) on July 25th, 2014 at $12.50. In approximately 4 months, Cresud SACIF has returned 15.20% as of today's recent price of $10.60.
CRESY: 10.52 (-0.11)

Cresud EPS of -ARS0.25
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:15AM CST

CRESY: 10.52 (-0.11)

Cresud S.A.C.I.F. y A. Announces Results for the First Quarter 2015 Ended September 2014
PR Newswire - Tue Nov 11, 6:52PM CST
Cresud S.A.C.I.F. y A. (NASDAQ: CRESY, BASE: CRES), today announces results for the First Quarter 2015 ended September 30, 2014.
CRESY: 10.52 (-0.11)

Cresud SACIF Shares Down 18.3% Since SmarTrend's Sell Call (CRESY)
Comtex SmarTrend(R) - Wed Nov 05, 11:08AM CST
SmarTrend identified a Downtrend for Cresud SACIF (NASDAQ:CRESY) on July 25th, 2014 at $12.50. In approximately 3 months, Cresud SACIF has returned 18.26% as of today's recent price of $10.22.
CRESY: 10.52 (-0.11)

Shares of CRESY Down 17.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Oct 29, 9:50AM CDT
SmarTrend identified a Downtrend for Cresud SACIF (NASDAQ:CRESY) on July 25th, 2014 at $12.50. In approximately 3 months, Cresud SACIF has returned 17.04% as of today's recent price of $10.37.
CRESY: 10.52 (-0.11)

Downtrend Call Working As Cresud SACIF Stock Falls 12.2% (CRESY)
Comtex SmarTrend(R) - Wed Oct 22, 9:39AM CDT
SmarTrend identified a Downtrend for Cresud SACIF (NASDAQ:CRESY) on July 25th, 2014 at $12.50. In approximately 3 months, Cresud SACIF has returned 12.16% as of today's recent price of $10.98.
CRESY: 10.52 (-0.11)

Cresud SACIF Down 10.6% Since SmarTrend Downtrend Call (CRESY)
Comtex SmarTrend(R) - Tue Sep 23, 9:23AM CDT
SmarTrend identified a Downtrend for Cresud SACIF (NASDAQ:CRESY) on July 25th, 2014 at $12.50. In approximately 2 months, Cresud SACIF has returned 10.64% as of today's recent price of $11.17.
CRESY: 10.52 (-0.11)

Cresud S.A.C.I.F. y A. Announces Results for Fiscal Year 2014 Ended June, 2014
PR Newswire - Tue Sep 09, 2:11AM CDT
Cresud S.A.C.I.F. y A. (NASDAQ: CRESY, BASE: CRES), today announces results for the Fiscal Year 2014 ended June 30, 2014.
CRESY: 10.52 (-0.11)

Cresud SACIF Shares Up 42.6% Since SmarTrend's Buy Recommendation (CRESY)
Comtex SmarTrend(R) - Mon Jul 21, 4:46PM CDT
SmarTrend identified an Uptrend for Cresud SACIF (NASDAQ:CRESY) on March 14th, 2014 at $9.62. In approximately 4 months, Cresud SACIF has returned 42.59% as of today's recent price of $13.71.
CRESY: 10.52 (-0.11)

Uptrend Call Working As Cresud SACIF Stock Rises 48.2% (CRESY)
Comtex SmarTrend(R) - Mon Jul 14, 11:00AM CDT
SmarTrend identified an Uptrend for Cresud SACIF (NASDAQ:CRESY) on March 14th, 2014 at $9.62. In approximately 4 months, Cresud SACIF has returned 48.21% as of today's recent price of $14.25.
CRESY: 10.52 (-0.11)

Cresud SACIF Shares Up 33.5% Since SmarTrend's Buy Recommendation (CRESY)
Comtex SmarTrend(R) - Mon Jun 30, 9:12AM CDT
SmarTrend identified an Uptrend for Cresud SACIF (NASDAQ:CRESY) on March 14th, 2014 at $9.62. In approximately 4 months, Cresud SACIF has returned 33.54% as of today's recent price of $12.84.
CRESY: 10.52 (-0.11)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Lauletta Birnbaum Earns Distinction in 2026 Chambers Guide

Updated Category News Views 209

Lauletta Birnbaum Recognized in the 2026 Chambers Spotlight Guide Lauletta Birnbaum has received prestigious recognition in the 2026 Chambers Spotlight Guide in the category of Corporate/Commercial Law. This honor highlights the firm's commitment to providing exceptional legal services to its clients. The Importance of Legal Recognition Chambers and Partners is recognized...

Continue Reading
Medicenna Therapeutics Showcases Advances in Cancer Treatment

Updated Category News Views 127

Medicenna Therapeutics Showcases Advances in Cancer Treatment Medicenna Therapeutics Corp. is making notable strides in the field of cancer immunotherapy. With a focus on developing innovative therapies, the company is gaining attention for its promising Superkines targeting a range of conditions, including cancer. One of their leading programs, MDNA11, has showcased...

Continue Reading
DÉKUPLE Reports Strong Growth in First-Half Earnings 2024

Updated Category News Views 258

DÉKUPLE reported its first-half earnings for 2024, showcasing an 8.8% rise in net sales, totaling €104.6 million. The figures signal a resilient company navigating a turbulent economic backdrop, but traders are already weighing the potential fallout. Key Financial Metrics: Profitability vs. Economic Headwinds The group's gross margin jumped 5.8%, hitting €83.5...

Continue Reading
Main Street Capital Corporation Declares 2025 Dividend Increases

Updated Category News Views 220

Regular Monthly Dividends Announced by Main Street Capital Main Street Capital Corporation (NYSE: MAIN) has taken a significant step forward in announcing its regular monthly dividends for the early part of 2025. The Board of Directors has declared a monthly dividend of $0.25 per share for January, February, and March of that year. This move showcases the company's...

Continue Reading
Exciting New Travel Offers Just for Travelzoo Club Members

Updated Category News Views 306

Exclusive Travel Offers for Club Members Travelzoo® (NASDAQ: TZOO), a leading platform for travel enthusiasts, has rolled out an enticing set of offers tailored specifically for its Club Members. These deals are meticulously negotiated to provide the best experiences at the most competitive prices. Whether you're looking for adventure or relaxation, there's something for...

Continue Reading